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Introduction: Metallothioneins (MTs) are a class of ubiquitously occurring low- 
molecular- weight cysteine- and metal- rich proteins containing sulfur- based metal 
clusters. MT- 3 exhibits neuro- inhibitory activity. The possibility to enhance the ex-
pression	of	MT-	3	or	protect	 it	 from	degradation	 is	an	attractive	 therapeutic	 target,	
because	 low	 levels	 of	 MT-	3	 were	 found	 in	 brains	 of	 Alzheimer’s	 disease	 (AD)	
patients.
Objectives: The primary objective of this study was to test an enhancement of MT- 3 
cellular	 concentration	 after	 MT-	3	 binding	 treatment,	 which	 could	 prevent	 MT-	3	
degradation.






about ten times the concentration that was needed for induction of MT- 3 expression. 
The	tested	compound	Benzothiazolone-	2	enhanced	apoptosis	and	necrosis,	but	it	was	
not	of	severe	effect.	About	80%	of	cells	were	still	viable.	There	was	no	serious	ROS-	
generation and no severe decrease in mitochondria numbers or stress induced endo-
plasmic reticulum changes after test treatments. The selected compound showed 
stable hydrophobic and electrostatic interaction during MT- 3 ligand interaction.
Conclusion:	Benzothiazolone-	2	compounds	significantly	enhanced	MT-	3	protein	and	
mRNA	levels.	The	compounds	can	be	looked	upon	as	one	of	the	probable	lead	com-
pounds	 for	 future	 drug	 designing	 experiments	 in	 the	 treatment	 of	 Alzheimer’s	
disease.
K E Y W O R D S
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qRT-PCR
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1  | INTRODUCTION
Alzheimer’s	 is	 the	most	 common	 form	of	 dementia;	 it	 is	 a	 term	 for	
memory damage and other intellectual capacities that are serious 
enough	 to	 impede	daily	 life.	Alzheimer’s	 disease	 accounts	 for	60	 to	





2009). The neurochemical elements responsible for this age- linked 
compulsive advance are still poorly described. The growing evidence 
supports	a	significant	role	for	biometals	such	as	copper	(Cu),	iron	(Fe),	
and	zinc	(Zn)	in	Aβ	accretion	and	neuronal	relapse	(Bush	&	Tanzi,	2008;	
Lovell,	 Robertson,	 Teesdale,	 Campbell,	 &	Markesbery,	 1998;	Miu	 &	
Benga,	 2006;	 Roberts,	 Ryan,	 Bush,	 Masters,	 &	 Duce,	 2012;	 Zatta,	
2008). The plasma Cu/MT ratio was found to be symptomatic of dis-
ease	advancement	in	AD	patients.	This	connotation	hints	at	a	probable	
connection between some pathological features of the disease and 
the MTs expression.
Metallothioneins (MTs) are a family of low- molecular weight and 
cysteine- rich proteins present in all eukaryotes. The MT family is en-
compassed	of	four	main	members	(MT-	1	to	MT-	4)	with	multiple	iso-
form subclasses. MT- 1 and MT- 2 are extensively expressed in almost 
all	tissues,	MT-	3	mainly	in	the	central	nervous	system	(CNS),	whereas	
MT-	4	 is	 present	 in	 squamous	 epithelial	 tissue	 (Palacios,	 Atrian,	 &	
Capdevila,	2011).
Many	 studies	 show	 that	 MT-	3	 mRNA	 is	 downregulated	 in	 AD	
brains	 (Barnham	 et	al.,	 2004;	 Carrasco	 et	al.,	 1999;	 Kim,	 Nam,	
Jeon,	Han,	 &	 Suk,	 2012;	Naruse	 et	al.,	 1994;	 Streit,	 2004;	Uchida,	
Takio,	Titani,	 Ihara,	&	Tomonaga,	1991;	Yu,	Lukiw,	Bergeron,	Niznik,	
&	Fraser,	2001);	 this	might,	 therefore,	contribute	to	 the	upsurge	of	
abnormal neuronal development that is associated with the disease. 
Degradation and deficiency in MT- 3 may lead to severe disruption of 
lysosomal biogenesis and cytoskeleton dynamics. Dysfunction of ly-
sosomes and actin cytoskeleton in MT- 3- null astrocytes contributed 
to	accumulation	of	 toxic	Aβs proteins and other damaged proteins. 
Apart	from	the	function	of	MT-	3	in	lysosomes	and	cytoskeleton,	ho-
meostasis of metal ions managed by MT- 3 may also play a key role in 
AD	(Bonda	et	al.,	2011).







APP/Aβ	 and	 reduce	 tau	pathology	 (Nixon,	2007).	Therefore,	 the	au-
tophagy	pathway	 is	 considerably	more	 complex	 in	AD	because	 it	 is	
simultaneously	induced	and	impaired.	APP/Aβ can be generated in au-
tophagosomes	at	low	levels	in	a	physiological	environment;	however,	
during disease conditions autophagosomes rapidly accumulate in the 
cell body and axonal terminals due to either impaired autophagic flux 
or	a	defected	endosomal	pathway	(Lee,	2009;	Lee,	Park,	Kim,	&	Koh,	
2010).
Martin et al. (2006) showed that in the Tg2576 transgenic mouse 
model	of	AD,	MT-	3	was	less	than	that	found	in	wild-	type	mice.	It	also	
establishes	 the	 roles	of	MT-	3	 and	Nnos	 in	Alzheimer’s	 disease.	The	
pathological changes that develop in this mode might be responsible 
for the degradation of MT- 3.
Roy,	 Kumar,	 Baig,	 Masarik,	 and	 Provaznik	 (2015)	 reported	 that	
natural-	based	 compounds	were	 effective	 in	modulating	Alzheimer’s	
disease. The in silico findings (which include studies of both pharma-
codynamics and pharmacokinetic properties) show that MT- 3 was 
able	to	bind	with	STOCK1N-	26544,	26929,	and	72593	compounds.	
The	 former	 two	 compounds	 contain	 Benzothiazolone-	2	 as	 a	 frag-
ment	 (3-	(2-	oxobenzo[d]thiazol-	3(2H)-	yl)propanoicacid	 (propanoic	
acid	of	Benzothiazolone-	2)	was	used	 in	the	synthesis).	 It	 is	obtained	
from Micrococcus sp. found in Tedania ignis,	whereas	the	 latter	com-
pound	is	a	modified	base	of	tryptamine	obtained	widely	in	plants,	such	
as Acacia spp.,	Lens esculenta,	Prosopsis juliflora,	 as	well	 as	 from	 the	
fungi Ponaeolus foenisicii,	Coprinus micaceus and from the gorgonian 
Paramuricia chamaeleon.
The current work validates the in silico findings for the com-
pounds. Experiments were performed to see the effect of these 
compounds	on	 live	 immortalized	human	microglia	 cells	 (SV40)	 and	
their effect on MT- 3 cellular concentration. The study also includes 
a binding free- energy calculation of the tested natural compound 
complexes and the standard controls through molecular dynamics 
simulations.
2  | MATERIALS AND METHODS







bovine serum in collagen- coated flasks. The medium was supple-
mented	with	penicillin	 (100	U/ml)	 and	 the	 cells	were	maintained	 at	
37°C	in	a	humidified	incubator	with	5%	CO2.
2.2 | RNA isolation and reverse transcription






turer’s	 instructions.	 The	 cDNA	 (20	μl)	 prepared	 from	 the	 total	RNA	
was	diluted	with	RNase-	free	water	 to	100	μl; 5 μl was then directly 
analyzed	using	the	LightCycler®480	II	System	(Roche).
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2.3 | Quantitative real- time polymerase 
chain reaction
qRT- PCR was performed using TaqMan gene expression as-
says	 and	 the	 LightCycler®480	 II	 System	 (Roche).	 The	 amplified	
DNA	was	 analyzed	 by	 the	 comparative	 Ct	method	 using	 β- actin 
as	a	 reference	gene.	The	primer	and	probe	sets	 for	ACTB	 (assay	
ID: Hs99999903_m1) and MT- 3 (assay ID: Hs01921768_s1) 
were	 selected	 from	 the	 TaqMan	 gene	 expression	 assays	 (Life	
Technologies,	USA).	The	qRT-	PCR	was	performed	under	 the	 fol-
lowing amplification conditions: total volume of 20 μl,	initial	incu-
bation at 50°C/2 min followed by denaturation at 95°C/10 min; 
then	45	cycles	at	95°C/15	s	and	at	60°C/1	min.	All	samples	were	
measured in duplicates.
2.4 | Immunodetection of MT- 3
Extraction of total protein from the cells was processed using the 
Pierce®	RIPA	Buffer	(Thermo	Scientific,	Rockford,	IL,	USA)	in	accord-
ance	 with	 the	 protocol	 provided.	 All	 protein	 concentrations	 were	
determined with the Pierce®	 BCA	 Protein	 Assay	 Kit.	 Protein	 sam-
ples were diluted to 10 μg/μl,	 then	 1	μl was slowly spotted onto a 
0.2μmImmun- Blot®	PVDF	membrane	(BioRad	Laboratories,	Hercules,	
CA,	USA)	and	air-	dried.	To	block	nonspecific	binding	sites,	the	mem-
branes	 were	 incubated	 using	 5%	 Blotting-	Grade	 Blocker	 (BioRad	
Laboratories)	 for	 one	 hour	 at	 room	 temperature.	 They	 were	 then	
incubated	using	Anti-	MT-	3	antibody	 (product	no.	 ab76618;	Abcam,	
Cambridge,	UK),	and	with	Anti-	β-	actin	(product	no.	ab8227;	Abcam).	
The	 antibody	was	 diluted	 1:1000	 using	 5%	 Blotting-	Grade	 Blocker	
(BioRad	Laboratories).
The	 membranes	 were	 then	 washed	 four	 times	 in	 PBS	 (Sigma-	
Aldrich,	St.	 Louis,	MO,	USA)	 for	 five	minutes	each,	before	being	 in-
cubated	with	 a	 secondary	 antibody	 (Peroxidase-	Labeled	Anti-	Rabbit	
IgG	(product	no.	PI-	1000;	Vector,	Burlingame,	CA,	USA)).	This	was	di-
luted	1:2000	using	5%	Blotting-	Grade	Blocker.	After	washing	in	PBS,	
all	 blots	were	visualized	on	photosensitive	 film.	Densitometric	 anal-
yses	 of	 the	membranes	were	 performed	 using	GeneSnap	 (Syngene,	
Cambridge,	UK).
2.5 | Cytotoxicity testing – MTT test
The suspension of 5000 cells was added to each well of standard mi-
crotiter	plates.	A	volume	of	200	μl	was	transferred	to	wells	2–11.	The	
medium (200 μl) was added to the first and the last column (1 and 
12(control)). The plates were incubated for 2 days at 37°C to ensure 
cell	growth.	The	medium	was	removed	from	columns	2–11.	Columns	
3–10	were	filled	with	200	μl	of	the	medium,	which	contained	an	in-
creased concentration of tested compound diluted in dimethylsulfox-
ide	(DMSO)	(0–1	μmol/l).	As	a	control,	columns	2	and	11	were	filled	
with the medium without tested compound.
The	 plates	were	 incubated	 for	 12	 and	 24	hr,	 then	 the	medium	
was	removed	and	the	cells	were	washed	in	PBS.	Columns	1–11	were	
filled with 200 μl	of	medium,	which	contained	50	μl of MTT (5 mg/
ml	 in	PBS)	 incubated	 in	a	humidified	atmosphere	 for	 four	hours	at	
37°C	and	then	wrapped	 in	aluminum	foil.	After	the	 incubation,	 the	
MTT- containing medium was replaced with 200 μl	of	99.9%	DMSO	
in	 order	 to	 dissolve	 the	 MTT-	formazan	 crystals.	 Subsequently,	
25 μl of glycine buffer was added to all wells; absorbance was im-
mediately	 determined	 to	 be	 570	nm	 (VersaMax	microplate	 reader,	
Molecular	Devices,	Sunnyvale,	CA,	USA).	All	samples	were	measured	
in duplicates.
2.6 | Confocal microscopy and cell staining
For	the	purpose	of	fluorescence	microscopy,	the	cells	were	cultivated	




in the cultivation media.
After	 the	 treatment,	 the	microscope	glass	slides	with	a	mono-
layer	 of	 cells	 were	 removed	 from	 the	 Petri	 dishes,	 rinsed	 in	 the	
cultivation	medium	without	 supplementation	 and	 PBS	 buffer	 and	
directly used for staining and fluorescence microscopy. The cells 
were incubated using the following highly specific fluorescent 
probes:
•	 Reactive	oxygen	species	were	visualized	using	CellROX	Deep	Red	
reagent	 (Life	Technologies,	 5	μmol/L,	 cell-permeant,	 life-cell	 stain	
with	absorption/emission	maxima	of	644/665	nm)
•	 Mitochondria	 were	 visualized	 using	 MitoTracker	 Green	 FM	 (Life	
Technologies,	300	nmol/L,	cell-permeant	life-cell	stain	with	absorp-
tion/emission	maxima	of	490/516	nm)
•	 The	 endoplasmic	 reticulum	 was	 visualized	 using	 ER-Tracker	 Red	
(Life	Technologies,	1	μmol/L,	cell-permeant,	 life-cell	stain	with	ab-
sorption/emission maxima of 587/615 nm).
After	 incubation	 (45	min,	 37°C,	 dark),	 the	 cells	 were	 washed	
three	 times	 with	 PBS	 buffer	 (0.05	mol/L,	 pH	 7.0)	 and	 observed	
under	 the	 confocal	microscope	 (Leica	TCS	 SP8	X,	Germany)	 using	
appropriate	excitation	and	emission	wavelengths.	Quantitative	anal-
ysis was performed typically from 10 fields of view. For image anal-
ysis,	 NIS	 elements	 BR	 Analysis	 (Nikon	 instruments,	 Tokyo,	 Japan)	
software	was	used.	Average	fluorescence	intensity	was	measured	in	
equally confluent fields of view. Results were compared statistically 
using t- tests.
2.7 | Flow cytometry analysis of cell death




cells following the exposure to Plumbagin.
Briefly,	the	cells	were	harvested	by	repetitive	pipetting	and	were	
washed	 two	 times	 with	 PBS	 (centrifuged	 at	 2000	rpm	 for	 5	min),	
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2.8 | Thermodynamic studies - MD simulation
The	 MM-	PBSA	 (Molecular	 Mechanics	 energies	 combined	 with	
Poisson–Boltzmann	Surface	Area)	approach,	combined	with	molecu-
lar	dynamics	 (MD)	 simulations,	 is	widely	used	 in	biomolecular	 com-
plexes as a way to estimate the protein ligand interaction energies and 
predict binding- free energies. It also evaluates the relative stabilities 
of	 different	 biomolecular	 structures.	 Additionally,	 it	 can	 be	 used	 to	
rescore	a	set	of	docked	complexes,	thereby	improving	the	ability	to	
distinguish between active and inactive lead molecules. The molecu-
lar dynamics simulation of MT- 3 docked complexes was performed 
using	 the	 GROMACS	 4.5.52	 (Berendsen	 et	al.,	 1995;	 Lindahl	 et	al.,	
2001)	package,	with	a	standard	GROMOS96	force	field	for	10,000	ps.	
Binding free- energy calculations were performed in this work for the 
ligand- bound complexes in order to provide further insight into the 
study.
3  | RESULTS
3.1 | The cytotoxic evaluation of benzothiazolone- 2- 
containing substances in microglia cells
The	 IC50	 value	 for	 STOCK1N-	26544	 is	 162.4	nmol/L,	 for	
STOCK1N-	26929	 it	 is	 100	nmol/L	 and	 for	 STOCK1N-	72593	 it	 is	
233.4	nmol/L.	 Thus,	 STOCK1N-	26929	 shows	 the	 highest	 effect	 on	
cell	 metabolic	 activity.	 Nevertheless,	 the	 IC50	 values	 for	 all	 tested	
molecules exceed the required concentration for the induction of 
MT- 3 expression by about 10 times (see Figure 1).
The	AnnexinV+/PI+	(Q2	quadrant)	depicts	late	necrosis	and	dying	
cells. The rate of the necrosis triggered by tested compounds did not 
exceed	4%	(only	showing	a	2.12%	increase,	compared	to	the	stained	
control).	 The	 Annexin	 V+/PI-	 (Q4)	 population	 represents	 apoptotic	
cells or early oncotic cells (see Figure 2). The largest amount of apop-
totic	or	early	oncotic	cells	was	found	in	10	nmol/L	STOCK1N-	72593	
after	 treatment	 (19.93%;	 12.31%	 increase	 compared	 to	 the	 stained	
control).	 Nevertheless,	 some	 portion	 of	 oncotic	 cells	 is	 able	 to	 re-
verse	oncosis	and	could	thereby	survive;	thus,	no	severe	 increase	in	
the total number of dying cells was found after treatment with tested 
compounds (see Figure 2).
Confocal microscopy revealed no significant morphological 
changes that had been induced by studied compounds. On the other 
hand,	we	used	two	probes	to	localize	mitochondria	and	the	endoplas-
mic	reticulum.	Whereas	MitoTracker	Green	FM	localizes	mitochondria	
regardless	 of	mitochondrial	 membrane	 potential,	 ER-	Tracker	 Red,	 a	
conjugate	of	green-	fluorescent	BODIPY®	TR	dye	and	glibenclamide,	
also	reflects	expression	of	sulphonylurea	receptors	of	ATP-	sensitive	
K+ channels and thereby reflects the ER function. The double- staining 
revealed no significant decrease in fluorescence corresponded to 




3.2 | Benzothiazolone- 2 enhances expression of  
MT- 3 in microglia cells
mRNA	expression	of	MT-	3	was	relatively	low	in	control	cells	without	
treatment.	All	 the	 three	 tested	compounds	enhanced	expression	of	
MT-	3	mRNA	in	both	tested	concentrations	(5	nmol/L	and	10	nmol/L,	
respectively)	(see	Figure	4a).
Expression of MT- 3 protein was undetectable in control cells with-
out	treatment.	All	the	three	tested	compounds	enhanced	expression	
of	 MT-	3	 protein	 (see	 Figure	4b).	 Nevertheless,	 compound	 72593	
caused	 visible	 enhancement	 only	 in	 5	nmol/L	 concentration.	 Other	
compounds enhanced expression of MT- 3 protein in tested concen-
trations	(see	Figure	4c).
F IGURE  1 MTT tests for selected compounds on cell lines. The half- maximal inhibition concentration (IC50) is indicated in the graph. Error 
bars indicate standard deviations
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3.3 | Thermodynamic studies on  
MT- 3- benzothiazolone complexes
Binding free- energy studies that validate the above findings were also 
performed.	The	 analysis	was	 carried	 out	 for	 the	 Benzothiazolone-	2	
docked	 complexes	 only,	 since	 the	 above	 results	 were	 encourag-
ing.	The	molecular	 docking	 representation	 is	 provided	 in	 Figure	 S1.	
It	 clearly	 states	 that	 the	 tested	 molecules	 (STOCK1N-	26929	 and	
STOCK1N-	26544)	 both	 have	 stable	 binding	 free-	energies	 values	 in	
the	form	of	potential,	polar,	and	nonpolar	solvation	energies	that	are	
comparable to the standard controls (Table 1). It also states that both 
hydrophobic and electrostatic interactions are important for protein 
ligand	interaction	in	case	of	MT-	3	for	Alzheimer’s	disease.
4  | DISCUSSION
The possibility to enhance the expression of MT- 3 or protect it 
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F IGURE  3  (Fluorescence	microscopy	analysis	of	mitochondria	and	endoplasmic	reticulum	(ER).	ER	is	stained	with	red	ER	tracker,	
mitochondria)	[MR1]	with	green	MitoTracker.	Reactive	oxygen	species	were	visualized	using	CellROX	Deep	Red	reagent
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enhancement of MT- 3 cellular concentration after MT- 3 binding 
treatment,	which	could	prevent	MT-	3	degradation.
The	three	compounds	under	investigation	were	STOCK1N-	26929,	
STOCK1N-	26544	 (Benzothiazolone-	2	 as	 fragment),	 and	 STOCK1N-	 
72593 (modified tryptamine- based).
The expression of MT- 3 protein was undetectable in control cells 
without	treatment.	All	three	tested	compounds	enhanced	concentra-
tion	of	MT-	3	protein	 in	cells	and	surprisingly	also	mRNA	concentra-
tion.	Nevertheless,	STOCK1N-	72593	was	relatively	less	effective. It is 
to be noted here that different concentrations of tested compounds 
can influence expression of MT- 3 differently. Epigenetic mechanisms 
and different types of activation of signaling pathways are suspected 
in	this	case.	Furthermore,	the	expression	of	MT-	3	could	be	regulated	
at	 the	 posttranscriptional	 level,	 which	was	 also	 observed	 in	 earlier	
studies	(Garrett	et	al.,	2005).	The	experiments	carried	out	did	not	as-
sume that triggering of MT- 3 expression should be in positive cor-
relation with tested compound concentration. The results showed 
that our compounds are able to influence MT- 3 expression. It is to 
be mention that our study is not oriented toward exact mechanism 
or	 to	show	exact	quantities	of	MT-	3	protein.	 In	our	opinion,	 two	of	
our	compounds	significantly	enhanced	MT-	3	protein	and	mRNA	levels.
The	three	tested	molecules	(STOCK1N-	26544,	STOCK1N-	26929,	
and	 STOCK1N-	72593)	 have	 no	 severe	 cytotoxic	 effects	 on	 neural	
tissue	(Figure	4).	IC50	values	of	tested	molecules	exceeded	about	10	
times the concentration that was needed for induction of MT- 3 ex-
pression (Figure 1). Our goal of the precise experiment is the assess-
ment of IC50 value. The findings also demonstrate that concentrations 
of	tested	compounds,	which	are	able	to	trigger	MT-	3	synthesis,	are	not	






STOCK1N-	72593	 after	 treatment	 (19.93%;	 12.31%	 increase	 com-
pared to the stained control).
Flow cytometric analysis on apoptosis/necrosis showed that a 
lower	dose	(5	nmol/L)	 induced	a	higher	toxic	effect	when	compared	
with	higher	doses	10	nmol/L.	This	 increase	was	not	 the	 severe	one	
(only	about	4%).	Epigenetic	mechanisms	and	different	 types	of	acti-
vation	of	signaling	pathways	are	suspected	in	this	case.	As	was	shown	
in	 other	 studies,	 mechanisms	 of	 drug-	induced	 cell	 death	 are	 often	
concentration	 dependent.	 Crosstalk	 between	 apoptosis,	 necrosis,	
and autophagy could be different in different drug concentrations 
and numbers of apoptotic cells could be attenuated because of some 
protective	autophagy	effects	(Kemp,	2017;	Miyoshi	et	al.,	2008;	Teng	
et	al.,	2016;	Torres	&	Horwitz,	1998).
According	 to	 fluorescence	 staining,	 no	 serious	ROS	generation	
and no severe decrease in mitochondria numbers or endoplasmic 
reticulum changes after test- treatment were found. This is very 
	important,	(because	oxidative	stress,	mitochondrial	dysfunction,	and	
endoplasmic reticulum stress have been implicated in beta- amyloid 
neurotoxicity).
The above findings were further validated by calculating the bind-




of selected compounds. (b) Dot blot for MT- 3. (c) (Protein level of 




















































TABLE  1 Binding free- energy calculation of the tested compounds and the standard controls
Ligand






SASA energy  
(kJ/mol)
Binding energy  
(kJ/mol)
BDBM50342769 −129.891	±	5.824 −25.876	±	5.056 71.608	±	5.845 −11.920	±	0.763 −96.078	±	11.107
BDBM9019 −83.033	±	9.812 −13.835	±	4.606 46.691	±	13.885 −8.855	±	1.547 −59.033	±	11.597
BDBM50260394 −101.236	±	10.190 −42.368	±	20.609 98.840	±	35.764 10.603	±	0.848 −55.367	±	20.694
STOCK1N-	26544 −60.097	±	41.578 −92.875	±	62.292 97.052	±	69.708 −7.644	±	5.449 −63.564	±	40.740
STOCK1N-	26929 −107.860	±	7.382 −71.870	±	14.138 118.127	±	28.044 −9.691	±	0.886 −71.294	±	21.520
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for	 1000	ps;	 several	 thermodynamic	 parameters	 (including	 RMSD,	




culates the potential energy of molecular mechanics and free- energy 
of solvation except entropy contribution.
Interaction	 energy	 for	 three	 control	 molecules	 with	 STOCK1N	
compounds	 was	 calculated	 with	 the	 MT-	3	 receptor,	 in	 order	 to	
compare	 it	 with	 the	 active	 binder.	 BDBM50342769,	 BDBM9019,	
BDBM50260394	 binding	 energies	 were	 approximately	 −96,	 −59,	
and	 −55	kJ/mol.	 If	 we	 look	 into	 the	 individual	 component	 of	 pre-
dicted	 free-	energy,	 van	 der	 Waals	 energies	 were	 dominant	 in	 the	
BDBM50342769,	 BDBM50260394	 binding	 with	 MT-	3.	 Similarly	
STOCK1N-	26929	 showed	 higher	 van	 der	Waals	 energy	 as	 well	 as	
good	binding	free-	energy	compared	to	STOCK1N-	26544	(low	contri-
bution of van der Waals energy). This suggests one of the major MT- 3 
binding interactions is governed by the hydrophobic forces. The sec-
ond	major	component	was	electrostatic	energy,	which	is	comparably	
higher	in	STOCK1N	molecules	than	in	controls.
The overall findings suggest that hydrophobic and electrostatic 
interaction is imperative for current MT- 3 ligand interaction. Polar sol-
vation and nonpolar solvation energies are comparable to the standard 
controls (Table 1).
5  | CONCLUSIONS
The current work has made an effort to see the effect of 
Benzothiazolone-	2	on	the	cellular	concentration	of	MT-	3.	Many	stud-
ies	 show	that	MT-	3	mRNA	 is	downregulated	 in	AD	brains	and	 that	
this	might,	therefore,	contribute	to	the	upsurge	of	abnormal	neuronal	
development associated with the disease.
Our	 previous	 findings	 suggests	 that	 Benzothiazolone-	2	 pos-
sesses better pharmacokinetic and pharmacodynamics properties. 
It also forms stable complex with MT- 3 according to molecular dy-
namics findings. The above findings were validated by screening the 
compounds	 against	 live	 immortalized	 human	microglia	 cells	 (SV40).	
This tested compound showed neither severed cytotoxicity nor did 
it	trigger	necrosis.	In	addition,	there	was	no	serious	ROS-	generation,	
decrease	in	mitochondrial	numbers,	stress-	induced	endoplasmic	retic-
ulum changes after test- treatments.	All	three	tested	compounds	en-
hanced cellular concentration of MT- 3 protein in cells and surprisingly 
also	mRNA	expression.
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